Logo image of APYX

APYX MEDICAL CORP (APYX) Stock Fundamental Analysis

NASDAQ:APYX - Nasdaq - US03837C1062 - Common Stock - Currency: USD

1.51  +0.06 (+3.82%)

Fundamental Rating

2

APYX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. APYX has a bad profitability rating. Also its financial health evaluation is rather negative. APYX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year APYX has reported negative net income.
In the past year APYX has reported a negative cash flow from operations.
APYX had negative earnings in each of the past 5 years.
APYX had a negative operating cash flow in each of the past 5 years.
APYX Yearly Net Income VS EBIT VS OCF VS FCFAPYX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M

1.2 Ratios

The Return On Assets of APYX (-46.84%) is worse than 66.31% of its industry peers.
Looking at the Return On Equity, with a value of -257.60%, APYX is doing worse than 80.75% of the companies in the same industry.
Industry RankSector Rank
ROA -46.84%
ROE -257.6%
ROIC N/A
ROA(3y)-30.15%
ROA(5y)-25.95%
ROE(3y)-53.34%
ROE(5y)-41.27%
ROIC(3y)N/A
ROIC(5y)N/A
APYX Yearly ROA, ROE, ROICAPYX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50

1.3 Margins

APYX has a Gross Margin (60.41%) which is in line with its industry peers.
In the last couple of years the Gross Margin of APYX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for APYX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y-0.22%
APYX Yearly Profit, Operating, Gross MarginsAPYX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 200 300

More info and screens

3

2. Health

2.1 Basic Checks

APYX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, APYX has about the same amount of shares outstanding.
APYX has more shares outstanding than it did 5 years ago.
APYX has a worse debt/assets ratio than last year.
APYX Yearly Shares OutstandingAPYX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
APYX Yearly Total Debt VS Total AssetsAPYX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -0.48, we must say that APYX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of APYX (-0.48) is comparable to the rest of the industry.
APYX has a Debt/Equity ratio of 3.07. This is a high value indicating a heavy dependency on external financing.
APYX's Debt to Equity ratio of 3.07 is on the low side compared to the rest of the industry. APYX is outperformed by 86.63% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.07
Debt/FCF N/A
Altman-Z -0.48
ROIC/WACCN/A
WACC9.77%
APYX Yearly LT Debt VS Equity VS FCFAPYX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 5.46 indicates that APYX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.46, APYX is in the better half of the industry, outperforming 79.68% of the companies in the same industry.
APYX has a Quick Ratio of 4.52. This indicates that APYX is financially healthy and has no problem in meeting its short term obligations.
APYX's Quick ratio of 4.52 is fine compared to the rest of the industry. APYX outperforms 78.61% of its industry peers.
Industry RankSector Rank
Current Ratio 5.46
Quick Ratio 4.52
APYX Yearly Current Assets VS Current LiabilitesAPYX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

APYX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -62.75%.
APYX shows a decrease in Revenue. In the last year, the revenue decreased by -3.50%.
The Revenue has been growing by 25.81% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-62.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.69%
Revenue 1Y (TTM)-3.5%
Revenue growth 3Y23.62%
Revenue growth 5Y25.81%
Sales Q2Q%-4.08%

3.2 Future

APYX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.30% yearly.
The Revenue is expected to grow by 7.01% on average over the next years.
EPS Next Y-15.98%
EPS Next 2Y16.55%
EPS Next 3Y11.64%
EPS Next 5Y14.3%
Revenue Next Year-9.98%
Revenue Next 2Y-3.94%
Revenue Next 3Y-0.32%
Revenue Next 5Y7.01%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
APYX Yearly Revenue VS EstimatesAPYX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
APYX Yearly EPS VS EstimatesAPYX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

APYX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year APYX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APYX Price Earnings VS Forward Price EarningsAPYX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APYX Per share dataAPYX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.55%
EPS Next 3Y11.64%

More info and screens

0

5. Dividend

5.1 Amount

APYX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APYX MEDICAL CORP

NASDAQ:APYX (2/21/2025, 8:01:32 PM)

1.51

+0.06 (+3.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-08 2024-11-08/bmo
Earnings (Next)03-13 2025-03-13/amc
Inst Owners41.63%
Inst Owner Change-93.32%
Ins Owners13.56%
Ins Owner Change0%
Market Cap61.28M
Analysts76
Price Target3.06 (102.65%)
Short Float %0.43%
Short Ratio3.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.03%
Min EPS beat(2)6.02%
Max EPS beat(2)26.05%
EPS beat(4)2
Avg EPS beat(4)-5.78%
Min EPS beat(4)-54.57%
Max EPS beat(4)26.05%
EPS beat(8)3
Avg EPS beat(8)-10.08%
EPS beat(12)5
Avg EPS beat(12)-3.86%
EPS beat(16)9
Avg EPS beat(16)4%
Revenue beat(2)1
Avg Revenue beat(2)0.18%
Min Revenue beat(2)-1.03%
Max Revenue beat(2)1.39%
Revenue beat(4)2
Avg Revenue beat(4)0.65%
Min Revenue beat(4)-3.19%
Max Revenue beat(4)5.42%
Revenue beat(8)3
Avg Revenue beat(8)-2.88%
Revenue beat(12)5
Avg Revenue beat(12)-2.52%
Revenue beat(16)9
Avg Revenue beat(16)1.73%
PT rev (1m)-7.69%
PT rev (3m)-7.69%
EPS NQ rev (1m)1.54%
EPS NQ rev (3m)1.54%
EPS NY rev (1m)0.35%
EPS NY rev (3m)0.54%
Revenue NQ rev (1m)2.87%
Revenue NQ rev (3m)2.87%
Revenue NY rev (1m)0.8%
Revenue NY rev (3m)-6.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.26
P/FCF N/A
P/OCF N/A
P/B 5.55
P/tB 5.55
EV/EBITDA N/A
EPS(TTM)-0.83
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS1.2
BVpS0.27
TBVpS0.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.84%
ROE -257.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.41%
FCFM N/A
ROA(3y)-30.15%
ROA(5y)-25.95%
ROE(3y)-53.34%
ROE(5y)-41.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y-0.22%
F-Score2
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 3.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 93.6%
Cap/Sales 1.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.46
Quick Ratio 4.52
Altman-Z -0.48
F-Score2
WACC9.77%
ROIC/WACCN/A
Cap/Depr(3y)90.17%
Cap/Depr(5y)101.8%
Cap/Sales(3y)1.59%
Cap/Sales(5y)2.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-62.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.69%
EPS Next Y-15.98%
EPS Next 2Y16.55%
EPS Next 3Y11.64%
EPS Next 5Y14.3%
Revenue 1Y (TTM)-3.5%
Revenue growth 3Y23.62%
Revenue growth 5Y25.81%
Sales Q2Q%-4.08%
Revenue Next Year-9.98%
Revenue Next 2Y-3.94%
Revenue Next 3Y-0.32%
Revenue Next 5Y7.01%
EBIT growth 1Y-7.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1.29%
EBIT Next 3Y19.81%
EBIT Next 5Y23.87%
FCF growth 1Y-6.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11.45%
OCF growth 3YN/A
OCF growth 5YN/A